NRBO News and Press, NeuroBo Pharmaceuticals Inc. From 08/03/23

NeuroBo Pharmaceuticals Receives First Site IRB Approval for its Phase 2a Clinical Trial Evaluating DA-1241 for the Treatment of NASH PR Newswire BOSTON , Aug. 3, 2023 /PRNewswire/ -- NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO), a clinical-stage biotechnolog...

2023-08-02 08:30:48 ET More on Oramed Oramed: Buyer Beware Oramed's Chinese partner HTIT completes phase 3 oral insulin trial; submits marketing Application in China; stock Up 17% Oramed stock falls 10% as Wainwright cuts rating on potential halt of drug trial ...

NeuroBo Pharmaceuticals Enters Into Term Sheet With MThera Pharma to Out-license NB-01 PR Newswire BOSTON , Aug. 2, 2023 /PRNewswire/ -- NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO), a clinical-stage biotechnology company on a quest to transform cardiomet...

2023-06-27 15:37:28 ET Have you ever dreamt of uncovering a hidden gem in the stock market, something that could turn your modest investment into a jackpot? Welcome to the world of penny stocks . Just like those unexpected finds at a garage sale, penny stocks—those little guy...

NeuroBo Pharmaceuticals' Novel GLP1R and GCGR Dual Agonist, DA-1726, Shown to Elicit Superior Weight Loss Efficacy Compared to Semaglutide and Tirzepatide in Preclinical Models PR Newswire Preclinical Data Also Show DA-1726 Effectively Reduces Body Weight and Glycemic Control ...

NeuroBo Pharmaceuticals Announces Acceptance of Two General Posters and One ePoster Theater Discussion of its Novel GLP1R and GCGR Dual Agonist, DA-1726, at the American Diabetes Association 83rd Scientific Sessions PR Newswire BOSTON , June 13, 2023 /PRNewswire/...

NeuroBo Pharmaceuticals, Inc. Appoints Pharmaceutical Industry Executive, Mark A. Glickman, to its Board of Directors PR Newswire BOSTON , May 12, 2023 /PRNewswire/ -- NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO), a clinical-stage biotechnology company on a q...

2023-05-02 08:26:46 ET The U.S. Food and Drug Administration (FDA) cleared NeuroBo Pharmaceuticals' ( NASDAQ: NRBO ) investigational new drug (IND) application seeking to start a trial of liver disease drug DA-1241. The company plans to begin a two-part, phase 2a trial of...

NeuroBo Pharmaceuticals Announces FDA Clearance of IND for a Phase 2a Clinical Trial of DA-1241 for the Treatment of NASH PR Newswire Initiation of Phase 2a Clinical Trial Expected to Occur in Q3 2023 BOSTON , May 2, 2023 /PRNewswire/ -- NeuroBo Pharmac...

2023-04-17 11:15:14 ET There were a lot of different micro-trends to watch when it came to penny stocks last week. Whether it was stocks with high short interest, a low float, insider trading activity, or unusual activity, take your pick. We noticed an even more active search for penn...